Taking our evidence together, our results unveil conceptual and functional avenues in HCC, with potential clinical implications, by demonstrating that HuR is a SUMOylation substrate in clinical HCC as well as in in vivo and cellular models of the disease. This evidence concerns the gene ELAVL1 and hepatocellular carcinoma.